Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low – Here’s What Happened

Posted by on Jun 23rd, 2026

Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $8.01 and last traded at $8.2348, with a volume of 309220 shares trading hands. The stock had previously closed at $8.53.

Analyst Upgrades and Downgrades

Separately, Citigroup lowered shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

View Our Latest Stock Analysis on SSMXY

Sysmex Stock Down 0.4%

The business has a 50 day moving average of $8.73 and a two-hundred day moving average of $9.11. The stock has a market capitalization of $5.35 billion, a PE ratio of 22.37 and a beta of 1.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26.

Sysmex (OTCMKTS:SSMXY – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Analysts predict that Sysmex Corporation ADR will post 0.37 EPS for the current year.

About Sysmex

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

Featured Articles

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.